Paper36588388
Advanced T and Natural Killer Cell Therapy for Glioblastoma.
Yoon WS and 1 other. J Korean Neurosurg Soc, 2023. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Advanced T and Natural Killer Cell Therapy for Glioblastoma. Papers, record 36588388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36588388
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References253
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36037304 | Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36037304 | PubMed |
| 2 | 18425106 | Up on the tightrope: natural killer cell activation and inhibition. | Nat Immunol | 2008 | https://conductscience.org/library/papers/18425106 | PubMed |
| 3 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 4 | 21790828 | Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. | Brain Pathol | 2012 | https://conductscience.org/library/papers/21790828 | PubMed |
| 5 | 29512837 | Natural killer cell cytotoxicity and its regulation by inhibitory receptors. | Immunology | 2018 | https://conductscience.org/library/papers/29512837 | PubMed |
| 6 | 32395366 | NK Cell-Based Immunotherapies in Cancer. | Immune Netw | 2020 | https://conductscience.org/library/papers/32395366 | PubMed |
| 7 | 30659023 | Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30659023 | PubMed |
| 8 | 29157300 | Prospects for combined use of oncolytic viruses and CAR T-cells. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/29157300 | PubMed |
| 9 | 28550091 | Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28550091 | PubMed |
| 10 | 26285657 | Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. | Stem Cells Transl Med | 2015 | https://conductscience.org/library/papers/26285657 | PubMed |
| 11 | 30250471 | Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. | Front Immunol | 2018 | https://conductscience.org/library/papers/30250471 | PubMed |
| 12 | 32132216 | Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32132216 | PubMed |
| 13 | 25837513 | Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. | Science | 2015 | https://conductscience.org/library/papers/25837513 | PubMed |
| 14 | 2643685 | Intratumoral LAK cell and interleukin-2 therapy of human gliomas. | J Neurosurg | 1989 | https://conductscience.org/library/papers/2643685 | PubMed |
| 15 | 30415658 | Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. | Mol Ther | 2018 | https://conductscience.org/library/papers/30415658 | PubMed |
| 16 | 21739672 | T cell exhaustion. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21739672 | PubMed |
| 17 | 8625188 | Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. | Cancer | 1995 | https://conductscience.org/library/papers/8625188 | PubMed |
| 18 | 31391096 | PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31391096 | PubMed |
| 19 | 17108138 | CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. | Cancer Res | 2006 | https://conductscience.org/library/papers/17108138 | PubMed |
| 20 | 21478334 | Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21478334 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42667630 | Advanced Materials for Biologics Delivery to Brain Tumors. | Adv Mater | 2026 | https://conductscience.org/library/papers/42667630 | PubMed |
| 42332740 | LAK to CIK continuum in glioma immunotherapy: a systematic review of efficacy and safety outcomes. | J Transl Med | 2026 | https://conductscience.org/library/papers/42332740 | PubMed |
| 42017986 | Interactions and communications in the glioblastoma microenvironment: potential targets for chemo-/radiotherapy. | Strahlenther Onkol | 2026 | https://conductscience.org/library/papers/42017986 | PubMed |
| 41961113 | Targeting the COX-2/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41961113 | PubMed |
| 41828675 | Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828675 | PubMed |
| 41655180 | "Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy". | Clin Exp Med | 2026 | https://conductscience.org/library/papers/41655180 | PubMed |
| 39329751 | Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme. | Cells | 2024 | https://conductscience.org/library/papers/39329751 | PubMed |
Genes81
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36588388
GET https://conductscience.org/api/papers/v1/36588388/references?page=2